ABCL
Price
$2.95
Change
+$0.03 (+1.03%)
Updated
Dec 24 closing price
62 days until earnings call
TRVI
Price
$4.00
Change
-$0.06 (-1.48%)
Updated
Dec 24 closing price
84 days until earnings call
Ad is loading...

ABCL vs TRVI

Header iconABCL vs TRVI Comparison
Open Charts ABCL vs TRVIBanner chart's image
AbCellera Biologics
Price$2.95
Change+$0.03 (+1.03%)
Volume$1.65M
CapitalizationN/A
Trevi Therapeutics
Price$4.00
Change-$0.06 (-1.48%)
Volume$441.5K
CapitalizationN/A
ABCL vs TRVI Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. TRVI commentary
Dec 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Buy and TRVI is a Buy.

Ad is loading...
COMPARISON
Comparison
Dec 25, 2024
Stock price -- (ABCL: $2.95 vs. TRVI: $4.00)
Brand notoriety: ABCL and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 66% vs. TRVI: 20%
Market capitalization -- ABCL: $871.33M vs. TRVI: $357.46M
ABCL [@Biotechnology] is valued at $871.33M. TRVI’s [@Biotechnology] market capitalization is $357.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $385.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABCL and TRVI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 5 TA indicator(s) are bullish while TRVI’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 5 bullish, 3 bearish.
  • TRVI’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than TRVI.

Price Growth

ABCL (@Biotechnology) experienced а +5.73% price change this week, while TRVI (@Biotechnology) price change was -11.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.85%. For the same industry, the average monthly price growth was -1.81%, and the average quarterly price growth was +3.32%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 25, 2025.

TRVI is expected to report earnings on Mar 19, 2025.

Industries' Descriptions

@Biotechnology (-0.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($871M) has a higher market cap than TRVI($357M). TRVI YTD gains are higher at: 198.507 vs. ABCL (-48.336). TRVI has higher annual earnings (EBITDA): -44.19M vs. ABCL (-202.4M). ABCL has more cash in the bank: 643M vs. TRVI (65.5M). TRVI has less debt than ABCL: TRVI (1.11M) vs ABCL (71.4M). ABCL has higher revenues than TRVI: ABCL (33M) vs TRVI (0).
ABCLTRVIABCL / TRVI
Capitalization871M357M244%
EBITDA-202.4M-44.19M458%
Gain YTD-48.336198.507-24%
P/E RatioN/AN/A-
Revenue33M0-
Total Cash643M65.5M982%
Total Debt71.4M1.11M6,415%
TECHNICAL ANALYSIS
Technical Analysis
ABCLTRVI
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 6 days ago
66%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QILGX38.210.44
+1.16%
Federated Hermes MDT Large Cap Growth IS
PBCJX46.560.49
+1.06%
Principal Blue Chip J
VVICX12.030.12
+1.01%
VOYA VACS Index Series SC Portfolio
CCSGX26.790.19
+0.71%
Conestoga SMid Cap Institutional
CONWX17.74N/A
N/A
Concorde Wealth Management

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with VCYT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+1.03%
VCYT - ABCL
56%
Loosely correlated
+0.46%
BEAM - ABCL
54%
Loosely correlated
+0.38%
PRME - ABCL
54%
Loosely correlated
-1.78%
AURA - ABCL
53%
Loosely correlated
+0.61%
DNA - ABCL
53%
Loosely correlated
-0.95%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with CMPX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then CMPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-1.48%
CMPX - TRVI
37%
Loosely correlated
-0.66%
BEAM - TRVI
32%
Poorly correlated
+0.38%
AURA - TRVI
32%
Poorly correlated
+0.61%
NTLA - TRVI
31%
Poorly correlated
-0.41%
ABCL - TRVI
31%
Poorly correlated
+1.03%
More